Prostate cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male patients with normal baseline sexual function (IIEF-5 score of 22–25), who had not used phosphodiesterase type 5 (PDE5) inhibitors or any other pharmacological or device-based interventions (as determined from patient self-report or clinical records); 2. No self-reported urinary incontinence; 3. Histologically confirmed diagnosis of prostate cancer by biopsy; 4. Localized prostate cancer (clinical stage cT1–T3N0M0); 5. Eligible for robot-assisted radical prostatectomy (RARP); 6. Complete preoperative and postoperative follow-up data, with a minimum follow-up duration of 12 months; 7. Provided written informed consent and agreed to participate in the study.
Exclusion criteria
Exclusion criteria: 1. History of pelvic radiotherapy, open or laparoscopic prostate surgery, or hormonal therapy for prostate cancer; 2. Presence of severe neurogenic bladder, overactive bladder, or urethral sphincter dysfunction; 3. Presence of moderate-to-severe cognitive impairment or psychiatric disorders that preclude compliance with follow-up assessments; 4. Intraoperative findings of tumor invasion of the bladder neck or urethra, or extensive pelvic lymph node metastasis; 5. Severe comorbidities (e.g., severe cardiopulmonary insufficiency) rendering the patient unfit for surgery; 6. Loss to follow-up or incomplete data during the postoperative follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative erectile function;IIEF-6 at 12 months postoperatively;Postoperative penile shortening;Postoperative peyronie’s disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| PSA persistence;Biochemical recurrence;Adjuvant treatment;Surgical margin status;Operation related indicators; | — |
Countries
China
Contacts
The First Affiliated Hospital of Fujian Medical University